Brief: Clinical utility and performance of Diaxonhit's AlloMap confirmed
03/06/2015 16:53
June 3 (Reuters) - Diaxonhit SA ALEHT.PA :
* Says clinical utility and performance of AlloMap heart
transplant test has been confirmed in European study
* Results from CARGO II study demonstrated performance
similar to previously published experience in United States
Source text for Eikon: ID:nHUG6YZ8bn
Further company coverage: ALEHT.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 6983920;))
Recent news on Eurobio Scientific SA
See all newsBrief: Eurobio Scientific EB Development Files Public Offer For Shares
Brief: Eurobio Scientific Says At End Of June 2024, Recorded Revenues Of 73.4 Mln Euros, Compared With 59.1 Mln Euros A Year Ago
Brief: Eurobio Scientific FY Core Business Revenues Up At EUR 130 Mln
Brief: Eurobio Scientific Cancels 694,300 Treasury Shares, Representing Around 6.34% Of Share Capital
Brief: Eurobio Scientific H1 Ebitda Up To EUR 13.4 Million